A new trading day began on Tuesday, with Ionis Pharmaceuticals Inc (NASDAQ: IONS) stock price up 2.58% from the previous day of trading, before settling in for the closing price of $35.24. IONS’s price has ranged from $23.95 to $52.34 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -8.88% over the past five years. Meanwhile, its annual earnings per share averaged -3.24%. With a float of $155.28 million, this company’s outstanding shares have now reached $159.04 million.
Let’s look at the performance matrix of the company that is accounted for 1069 employees. In terms of profitability, gross margin is 97.75%, operating margin of -65.85%, and the pretax margin is -64.7%.
Ionis Pharmaceuticals Inc (IONS) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Ionis Pharmaceuticals Inc is 2.44%, while institutional ownership is 104.26%. The most recent insider transaction that took place on May 01 ’25, was worth 477,900. In this transaction Director of this company bought 15,000 shares at a rate of $31.86, taking the stock ownership to the 50,219 shares. Before that another transaction happened on Apr 16 ’25, when Company’s EVP, Corp and Development Ops sold 680 for $28.37, making the entire transaction worth $19,292. This insider now owns 56,660 shares in total.
Ionis Pharmaceuticals Inc (IONS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -3.24% per share during the next fiscal year.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Trading Performance Indicators
Here are Ionis Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.62. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.98, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -3.18 in one year’s time.
Technical Analysis of Ionis Pharmaceuticals Inc (IONS)
Ionis Pharmaceuticals Inc (NASDAQ: IONS) saw its 5-day average volume 1.62 million, a negative change from its year-to-date volume of 1.66 million. As of the previous 9 days, the stock’s Stochastic %D was 37.22%. Additionally, its Average True Range was 1.13.
During the past 100 days, Ionis Pharmaceuticals Inc’s (IONS) raw stochastic average was set at 89.38%, which indicates a significant increase from 74.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 26.08% in the past 14 days, which was lower than the 44.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $32.13, while its 200-day Moving Average is $35.18. Nevertheless, the first resistance level for the watch stands at $36.71 in the near term. At $37.26, the stock is likely to face the second major resistance level. The third major resistance level sits at $38.20. If the price goes on to break the first support level at $35.22, it is likely to go to the next support level at $34.28. Assuming the price breaks the second support level, the third support level stands at $33.73.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Key Stats
With a market capitalization of 5.75 billion, the company has a total of 159,159K Shares Outstanding. Currently, annual sales are 705,140 K while annual income is -453,900 K. The company’s previous quarter sales were 131,610 K while its latest quarter income was -146,940 K.
